HCPCS code J2779: Susvimo ranibizumab, per 0.1 mg2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J2779 covers

J2779 represents ranibizumab administered through the Susvimo implant, a refillable intravitreal drug delivery system used to treat neovascular, or wet, age-related macular degeneration. Retina specialists and other ophthalmologists implant the device and provide its subsequent refills in ophthalmic surgical or procedure settings. The drug enters the eye through the implant rather than through a conventional intravitreal injection at each treatment visit.

CMS assigns physician fee schedule status E, meaning the code is excluded from the physician fee schedule. When Medicare covers the drug, payment is under another payment method; the HCPCS pricing method identifies it as a Part B drug generally paid using CMS quarterly Average Sales Price files. Coverage is left to the Medicare contractor’s judgment. Each billing unit represents 0.1 mg of ranibizumab. Report the drug separately from the procedure performed to insert or refill the implant, using the applicable procedure coding.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J2779 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

J2779 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the J2779 rate is calculated

Each of J2779’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J2779

J2779 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J2779 compared with similar codes

How to choose

J2778Ranibizumab injectionPer 0.1 mg

Choose J2779 for ranibizumab delivered through Susvimo; J2778 represents ranibizumab administered by conventional intravitreal injection.

J2777Faricimab injectionPer 0.1 mg

J2777 identifies faricimab, a different drug. J2779 identifies ranibizumab administered through the Susvimo implant.

0770TVR-assisted therapyWith physiologic monitoring

J2779 reports the ranibizumab drug in 0.1 mg units. CPT 0770T describes the implant refill and maintenance service, not the drug.

Codes related to J2779

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates